Exela Pharma Sciences LLC is categorized under Research and Development Laboratories in Lenoir, NC .
Exela Pharma Sciences LLC was established in 0, and today employs 1 to 4, earning Unknown per year. This is a Research and Development Laboratories business, which does work in the B2B market, and is classified as a Research and Development Laboratories, under code number 5417110 by the NAICS.
If you are seeking more information, feel free to contact Phanesh Koneru, Owner at the company’s single location by writing to 637 Nuway Circle, Lenoir, North Carolina NC 28645 or by phoning (828) 758-5474. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Exela Pharma Sciences LLC |
| Contact Person: | Phanesh Koneru, Owner |
| Address: | 637 Nuway Circle, Lenoir, North Carolina 28645 |
| Phone Number: | (828) 758-5474 |
| Website Address: | exela.us |
| Annual Revenue (USD): | Unknown |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Research and Development Laboratories |
| SIC Code: | 8731 |
| NAICS Code: | 5417110 |
| Share This Business: |
Exela Pharma Sciences LLC was started in 0 to provide professional Research and Development Laboratories under the SIC code 8731 and NAICS code 5417110. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.
Feel free to contact Phanesh Koneru, Owner for inquiries that concern Exela Pharma Sciences LLC by calling the company number (828) 758-5474, as your correspondence is most welcome. Additionally, the physical location of the single location of Exela Pharma Sciences LLC can be found at the coordinates 35.94757,-81.53048 as well as the street address 637 Nuway Circle in Lenoir, North Carolina 28645.
For its online presence, you may visit Exela Pharma Sciences LLC’s website at exela.us and engage with its social media outlets through on Twitter and on Facebook.